ArticleParasitology research2011
Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
Article in Parasitology research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis.Antimicrobial agents and chemotherapy · 2023Article
- Revisiting nature: a review of iridoids as a potential antileishmanial class.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022Review
- Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.Expert opinion on drug metabolism & toxicology · 2019Review
- Efficacy of FourMedicines (Basel, Switzerland) · 2018Article
- Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis.PLoS neglected tropical diseases · 2016Article
- Apoptosis mediated leishmanicidal activity of Azadirachta indica bioactive fractions is accompanied by Th1 immunostimulatory potential and therapeutic cure in vivo.Parasites & vectors · 2015Article
- Therapeutic switching: from antidermatophytic essential oils to new leishmanicidal products.Memorias do Instituto Oswaldo Cruz · 2015Article
- Plant-derived compounds in treatment of leishmaniasis.Iranian journal of veterinary research · 2015Review
- Drug strategies targeting CYP51 in neglected tropical diseases.Chemical reviews · 2014Review
- Evaluation of the effect of miltefosine on Trichomonas vaginalis.Parasitology research · 2014Article
- Exploring the role of medicinal plant-based immunomodulators for effective therapy of leishmaniasis.Frontiers in immunology · 2014Review
- Leishmania major protein disulfide isomerase as a drug target: enzymatic and functional characterization.Parasitology research · 2012Article
- The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.Parasitology research · 2012Article
- A Picrorhiza kurroa derivative, picroliv, attenuates the development of dextran-sulfate-sodium-induced colitis in mice.Mediators of inflammation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemotherapy of visceral leishmaniasis (VL) has several limitations including resistance and toxicity of the existing drugs. Downregulation of immune system further aggravates the problems. To combat this situation, leishmanicidal efficacy of already marketed standard antifungal drug, fluconazole under the approach of "therapeutic switching" in combination with standard antileishmanial drug, miltefosine, and a potent immunomodulator agent, picroliv, were evaluated in hamsters infected with Leishmania donovani. Animals treated with fluconazole (50 mg/kg × 5 days, oral (p.o.)) + miltefosine (5 mg/kg × 5 days, p.o.) showed enhancement in antileishmanial efficacy (77%), reactive nitrogen species, reactive oxygen species, hydrogen peroxide, and phagocytosis index as compared to those treated with individual drugs. Addition of picroliv to this combination further increased the antileishmanial efficacy from 77% to 88%. Upregulation of cell-mediated immunity was also observed in animals of this group which strengthens the immunomodulatory role of picroliv. These findings suggest a new option for antileishmanial chemotherapy at lower cost and toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.